Recently, a meta-analysis comparing [18F]-FES uptake with ER expression measured immunohistochemically in a biopsy sample, found a 78% overall sensitivity and 98% specificity to detect ER expression in non-liver metastases in patients with breast cancer. Here, ESR1 is linked to breast cancer.